Protherics PLC Notification of Director's Interests London, UK; Brentwood, TN, US: 10 July 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Sections 3.1.4R of the FSA Disclosure and Transparency Rules, announces that 916,202 ordinary shares (the "Shares") were issued to Jacques Gonella, Non-executive Director of Protherics, on 9 July 2008 following their admission to the Official List of the Financial Services Authority. The Shares form part of the allotment of 1,741,911 ordinary shares (details of which are contained in the Company's announcement dated 4 July 2008) made pursuant to the MacroMed Acquisition Agreement (the "Agreement") approved by shareholders at the Company's Extraordinary General Meeting held on 3 January 2007. Details of the Agreement are contained in the Company's announcement dated 7 December 2006. In accordance with the Agreement the issue price of the shares is 69.69 pence per share. Following the issuance of the Shares, Dr Gonella holds a beneficial interest in 9,162,017 ordinary shares in the Company representing 2.677% of the issued share capital of 342,159,034 ordinary shares. / Ends / For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113 New York: John Capodanno +1 212 850 5600 Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com